LTRN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 7.31%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $62,500.00

Lantern Pharma Insider Trading History Chart

Lantern Pharma Share Price & Price History

^$3.85

▼ -0.05 (-1.28%)

As of 03/25/2025 05:00 PM ET

Days: 30 | 90 | 365

Lantern Pharma Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/23/2024	Aaron G.L. Fletcher	Major Shareholder	Sell	10,000	$6.25	$62,500.00	59,326
2/28/2024	Aaron G.L. Fletcher	Major Shareholder	Sell	74,297	$4.85	$360,340.45	62,088
1/17/2024	Aaron G.L. Fletcher	Major Shareholder	Sell	58,889	$4.20	$247,333.80	73,646
11/29/2023	Leslie W Kreis	Major Shareholder	Sell	145,348	$3.44	$499,997.12	217,553
11/8/2022	Leslie W Kreis	Major Shareholder	Sell	350,000	$4.40	$1,540,000.00	71,774

SEC Filings (Institutional Ownership Changes) for Lantern Pharma (NASDAQ:LTRN)

28.62% of Lantern Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Lantern Pharma Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/17/2025	Two Sigma Investments LP	16,545	$53K	0.0%	-51.8%	0.153%
2/14/2025	Voss Capital LP	50,000	$0.16M	0.0%	N/A	0.464%
2/13/2025	NewEdge Advisors LLC	68,359	$0.22M	0.0%	-50.2%	0.634%
2/13/2025	Renaissance Technologies LLC	87,300	$0.28M	0.0%	+3.9%	0.810%
2/10/2025	BIOS Capital Management LP	1,207,709	$3.85M	4.1%	N/A	11.203%
2/7/2025	CM Management LLC	200,000	$0.64M	0.6%	+8.1%	1.855%
1/31/2025	Sanctuary Advisors LLC	10,000	$32K	0.0%	N/A	0.093%
1/24/2025	DAVENPORT & Co LLC	25,814	$82K	0.0%	-52.0%	0.239%
1/22/2025	Perigon Wealth Management LLC	14,600	$47K	0.0%	-49.5%	0.135%
11/20/2024	Westside Investment Management Inc.	30,650	$0.11M	0.0%	+166.5%	0.284%
8/9/2024	Renaissance Technologies LLC	81,800	$0.38M	0.0%	+24.5%	0.760%
8/9/2024	Dimensional Fund Advisors LP	18,413	$86K	0.0%	+55.7%	0.171%
8/2/2024	CM Management LLC	80,000	$0.37M	0.3%	+23.1%	0.743%
7/17/2024	Westside Investment Management Inc.	11,500	$54K	0.0%	N/A	0.107%
5/14/2024	CM Management LLC	65,000	$0.57M	0.5%	-18.8%	0.604%
5/10/2024	Tocqueville Asset Management L.P.	19,000	$0.17M	0.0%	N/A	0.177%
4/10/2024	Pathway Financial Advisors LLC	25,001	$0.22M	0.1%	-12.3%	0.233%
2/12/2024	Redmond Asset Management LLC	40,662	$0.17M	0.1%	-12.6%	0.374%
2/8/2024	Meridian Wealth Management LLC	19,660	$84K	0.0%	+18.0%	0.181%
2/1/2024	Sigma Planning Corp	11,875	$51K	0.0%	-34.5%	0.109%
2/1/2024	Pathway Financial Advisors LLC	28,501	$0.12M	0.0%	-13.0%	0.262%
10/30/2023	Pathway Financial Advisors LLC	32,771	$0.11M	0.0%	+134.1%	0.302%
10/17/2023	Meridian Wealth Management LLC	16,660	$57K	0.0%	N/A	0.153%
8/10/2023	Carlson Capital L P	95,000	$0.54M	0.0%	-23.9%	0.875%
8/4/2023	CM Management LLC	75,000	$0.42M	0.4%	+25.0%	0.691%
7/19/2023	Pathway Financial Advisors LLC	14,001	$79K	0.0%	N/A	0.129%
2/9/2023	CM Management LLC	60,000	$0.36M	0.4%	+20.0%	0.552%
2/9/2023	Wolff Wiese Magana LLC	27,098	$0.16M	0.1%	-11.0%	0.250%
2/7/2023	Lynwood Capital Management Inc.	12,000	$73K	0.1%	N/A	0.110%
11/15/2022	Carlson Capital L P	168,000	$0.80M	0.1%	-1.2%	1.547%
11/4/2022	CM Management LLC	50,000	$0.24M	0.3%	+10.9%	0.462%
8/8/2022	CM Management LLC	45,100	$0.26M	0.3%	+33.6%	0.416%
7/15/2022	Wolff Wiese Magana LLC	31,575	$0.18M	0.1%	-12.7%	0.292%
7/11/2022	Sanders Morris Harris LLC	366,030	$2.06M	0.5%	-4.7%	3.379%
5/9/2022	CM Management LLC	33,765	$0.24M	0.2%	N/A	0.312%
5/9/2022	Wolff Wiese Magana LLC	36,155	$0.26M	0.2%	+5.9%	0.334%
4/11/2022	Sanders Morris Harris LLC	384,228	$2.75M	0.5%	+14.2%	3.564%
2/4/2022	Envestnet Asset Management Inc.	10,542	$84K	0.0%	N/A	0.094%
2/4/2022	Redmond Asset Management LLC	49,187	$0.39M	0.1%	+3.7%	0.440%
2/3/2022	Advisor Group Holdings Inc.	5,331	$43K	0.0%	+92.5%	0.048%
2/2/2022	Sanders Morris Harris LLC	336,425	$2.57M	0.4%	N/A	3.007%
2/2/2022	Sigma Planning Corp	17,600	$0.14M	0.0%	N/A	0.157%
1/14/2022	Spire Wealth Management	4,050	$32K	0.0%	+285.7%	0.036%
11/9/2021	BlackRock Inc.	23,074	$0.26M	0.0%	-8.1%	0.206%
11/5/2021	Advisor Group Holdings Inc.	2,770	$31K	0.0%	+177.0%	0.025%
11/2/2021	Raymond James & Associates	25,879	$0.29M	0.0%	N/A	0.231%
10/29/2021	GWM Advisors LLC	155,859	$1.74M	0.0%	+3.0%	1.394%
10/22/2021	Redmond Asset Management LLC	47,442	$0.53M	0.2%	+4.3%	0.424%
10/15/2021	Wolff Wiese Magana LLC	35,316	$0.40M	0.3%	+24.7%	0.316%
8/16/2021	Corriente Advisors LLC	656,364	$9.58M	5.2%	-8.0%	5.869%
8/13/2021	Geode Capital Management LLC	55,479	$0.81M	0.0%	+21.1%	0.496%
8/13/2021	Vanguard Group Inc.	269,429	$3.93M	0.0%	+4.0%	2.409%
8/11/2021	Bank of New York Mellon Corp	26,765	$0.39M	0.0%	+127.3%	0.239%
7/31/2021	GWM Advisors LLC	151,316	$2.21M	0.1%	N/A	1.353%
5/21/2021	Citadel Advisors LLC	11,192	$0.20M	0.0%	N/A	0.100%
5/18/2021	Millennium Management LLC	42,106	$0.76M	0.0%	N/A	0.377%
5/18/2021	Morgan Stanley	50,702	$0.92M	0.0%	+81.6%	0.453%
5/18/2021	Corriente Advisors LLC	713,806	$12.95M	4.8%	N/A	6.384%
5/18/2021	Citadel Advisors LLC	11,192	$0.20M	0.0%	N/A	0.100%
5/13/2021	Bank of New York Mellon Corp	11,775	$0.21M	0.0%	N/A	0.105%
5/12/2021	Northern Trust Corp	12,629	$0.23M	0.0%	N/A	0.113%
5/12/2021	Geode Capital Management LLC	45,830	$0.83M	0.0%	N/A	0.410%
5/12/2021	UBS Group AG	2,166	$39K	0.0%	N/A	0.019%
5/7/2021	BlackRock Inc.	23,650	$0.43M	0.0%	+351.2%	0.212%
5/6/2021	Redmond Asset Management LLC	44,991	$0.82M	0.3%	N/A	0.402%
5/3/2021	Flagship Harbor Advisors LLC	147,671	$2.68M	0.3%	N/A	1.321%
4/28/2021	US Bancorp DE	2,000	$36K	0.0%	N/A	0.018%
4/15/2021	Wolff Wiese Magana LLC	27,075	$0.49M	0.4%	N/A	0.242%

Data available starting January 2016

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Today's Range

Now: $3.85

$3.80

$4.00

50 Day Range

MA: $4.26

$3.49

$5.40

52 Week Range

Now: $3.85

$2.79

$10.77

Volume

16,587 shs

Average Volume

86,383 shs

Market Capitalization

$41.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.64

Who are the company insiders with the largest holdings of Lantern Pharma?: Lantern Pharma's top insider investors include:
Leslie W Kreis (Major Shareholder)
Aaron GL Fletcher (Major Shareholder)
Learn More about top insider investors at Lantern Pharma.
Who are the major institutional investors of Lantern Pharma?: Lantern Pharma's top institutional investors include:
BIOS Capital Management LP — 11.20%
CM Management LLC — 1.86%
Renaissance Technologies LLC — 0.81%
NewEdge Advisors LLC — 0.63%
Voss Capital LP — 0.46%
DAVENPORT & Co LLC — 0.24%
Learn More about top institutional investors of Lantern Pharma stock.
Which major investors are selling Lantern Pharma stock?: In the previous quarter, LTRN stock was sold by these institutional investors:
NewEdge Advisors LLC
DAVENPORT & Co LLC
Two Sigma Investments LP
Perigon Wealth Management LLC
Citadel Advisors LLC
Which major investors are buying Lantern Pharma stock?: In the last quarter, LTRN stock was acquired by institutional investors including:
BIOS Capital Management LP
Voss Capital LP
CM Management LLC
Sanctuary Advisors LLC
Renaissance Technologies LLC